←
EAS Congress5,985 posts
EAS Congress avatar

EAS Congress

@EASCongress

EAS is advancing & exchanging knowledge concerning the causes, natural history, treatment & prevention of atherosclerotic disease. #EASCongress2026

◷ Joined December 2010▧ 1,696 Photos and videos
Federica Fogacci avatar
⟳ EAS Congress retweeted
Federica Fogacci@FedericaFogacci·May 31

Some congress moments stay with you. Presenting my SaaG poster at #EASCongress2026 on the intersection between reproductive planning and lipid management, and discussing it with Marianne Benn as moderator, was one of them. A real honour, and a very thoughtful exchange #MyEAS2026

Post attachment
Federica Fogacci avatar
⟳ EAS Congress retweeted
Federica Fogacci@FedericaFogacci·May 31

Very glad to 🗣️ Nick Nurmohamed’s work on inflam plaques during the EAS Research Grant Winners session. The question is no longer whether inflam matters in ath, but how we identify biologically active plaques and translate that into better clinical decisions. Great work, Nick! 👏

Post attachmentPost attachment
Federica Fogacci avatar
⟳ EAS Congress retweeted
Federica Fogacci@FedericaFogacci·May 31

The real value of a programme like this is not only what it gives you during the fellowship. It is what stays afterwards: a network, a sense of belonging, and the confidence to take your place in the scientific conversation #EASCongress2026 #MyEAS2026

Post attachment

That is why I was very happy to speak about the EAS Young Fellows Programme at #EASCongress2026. For me, it has been much more than a fellowship: a place where ideas are challenged, collaborations start, and young researchers learn to contribute with confidence #MyEAS2026

Post attachmentPost attachment
Federica Fogacci avatar
⟳ EAS Congress retweeted
Federica Fogacci@FedericaFogacci·May 31

That is why I was very happy to speak about the EAS Young Fellows Programme at #EASCongress2026. For me, it has been much more than a fellowship: a place where ideas are challenged, collaborations start, and young researchers learn to contribute with confidence #MyEAS2026

Post attachmentPost attachment
Federica Fogacci avatar
⟳ EAS Congress retweeted
Federica Fogacci@FedericaFogacci·May 31

My take 🏡 from the EAS Stage: Social media is not the opposite of serious medicine. Used responsibly, it helps scientific societies enter the space where opinions, doubts and decisions are formed. That is not marketing. That is prevention #EASCongress2026 #MyEAS2026 @society_eas

Post attachmentPost attachment

I was grateful to bring the Italian perspective to this EAS Stage discussion. Italy has key building blocks: governance, prevention networks, access pathways, monitoring and intensification. The next step is connection 🤝 #EASCongress2026 @society_eas @KatiOorni

Post attachment
Federica Fogacci avatar
⟳ EAS Congress retweeted
Federica Fogacci@FedericaFogacci·May 31

In prevention, the weakest point is often the drop off. Risk is identified, but the patient does not reach treatment. Treatment is started, but not intensified. Therapy is prescribed, but trust is missing. SAFE HEARTS needs to protect the whole chain #EASCongress2026 @society_eas

Post attachmentPost attachment
Jamal Rana, MD avatar
⟳ EAS Congress retweeted
Jamal Rana, MD@JamalRanaMD·May 31

This year's @EASCongress #2026 was phenomenal. Congratulations to @BNordestgaard, @ProfKausikRay and the whole team! ⚡ The Anistschkow Prize 2026 winner Prof Heribert Shunkert shared his decades of groundbreaking work in opening talk on "Interplay of #genetics and modifiable risk in #atherosclerosis" ⚡ Joint sessions of @nationallipid - #EAS and @escardio -#EAS were packed to capacity. ⚡ Best part, I got to meet and learn from my friends and thought leaders from around the world! @drpablocorral @ErinMichos @DineshKalra @FedericaFogacci @skathire @CBallantyneMD @society_eas See you all next year in #Gothenburg!

Post attachment
Dr Jhunu Mukherjee, MD( Psy) avatar
⟳ EAS Congress retweeted
Dr Jhunu Mukherjee, MD( Psy)@JhunuDr·May 29

The future #EASCongress2026 ANGPTL3 silencing is entering a very interesting space in lipid lowering. Preclinical and Phase 1 data on AZD1705, a liver targeted approach aiming to lower atherogenic lipoproteins

Post attachment